Cephalosporin Drugs Global Market Report 2025

The cephalosporin drugs market size has grown steadily in recent years. It will grow from $16.56 billion in 2024 to $17.34 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. Growth during the historical period can be credited to the rising prevalence of bacterial infections, the escalation of antibiotic resistance, increased healthcare spending, and the growing demand for generic medications.

The cephalosporin drugs market size is expected to see steady growth in the next few years. It will grow to $20.64 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. Growth projected for the forecast period can be attributed to the expanding elderly population, heightened awareness of bacterial infections, a rise in hospital admissions, and continued development of new cephalosporin formulations. Key trends anticipated during this period include innovations in drug formulation technologies, integration of advanced technology in manufacturing, the emergence of novel cephalosporin derivatives, and progress in drug delivery systems.

The increasing occurrence of infectious diseases is projected to drive the expansion of the cephalosporin drugs market in the coming years. Infectious diseases are illnesses triggered by microorganisms such as bacteria, viruses, fungi, or parasites, which can be transmitted from one person to another. This rise in infectious diseases is primarily attributed to the growing issue of antimicrobial resistance, which renders previously manageable infections more difficult to treat, resulting in more persistent and widespread illness. Cephalosporin drugs are instrumental in treating these infections due to their broad-spectrum antibacterial properties, making them effective against a wide range of bacterial pathogens. They help shorten treatment duration by delivering rapid and effective relief, thereby enhancing patient recovery. For example, in November 2023, the U.S. Department of Health and Human Services reported that newly documented chronic hepatitis B cases increased by 11% in 2022 compared to the previous year. Consequently, the rising incidence of infectious diseases is contributing to the growth of the cephalosporin drugs market.

Leading players in the cephalosporin drugs market are concentrating on creating advanced treatment options, such as those targeting gram-negative bacterial infections, to combat antimicrobial resistance and address the increasing global burden of drug-resistant infections. Treating gram-negative bacterial infections involves using specialized antibiotics to target bacteria that possess a distinct cell wall structure, which makes them inherently more resistant to conventional antibiotics. For instance, in May 2024, Shionogi & Co. Ltd., a pharmaceutical firm based in Japan, introduced FETROJA (Cefiderocol), a new antibiotic developed to combat severe gram-negative bacterial infections, including drug-resistant strains. Its innovative Trojan horse strategy enables it to bypass multiple resistance mechanisms, offering a vital therapeutic option for patients with limited alternatives.

In January 2024, Venatorx Pharmaceuticals Inc., a pharmaceutical company based in the U.S., formed a partnership with Menarini Group to secure exclusive rights for the commercialization of cefepime-taniborbactam across 96 countries. This collaboration is intended to enhance global availability of this next-generation antibiotic, designed to target multidrug-resistant bacterial infections. Menarini Group, headquartered in Italy, manufactures and develops cephalosporin-based drugs.

Major players in the cephalosporin drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Baxter International, Macleods Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Mankind Pharma Limited, Aristo Pharmaceuticals Ltd, Hetero Drugs Ltd, Covalent Laboratories Private Limited.

North America was the largest region in the cephalosporin drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cephalosporin drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cephalosporin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cephalosporin drugs belong to the beta (β)-lactam class of antibiotics and are used to combat bacterial infections by disrupting the synthesis of the bacterial cell wall, resulting in cell death. These broad-spectrum antibiotics are categorized into generations based on their range of antimicrobial activity. Cephalosporins are frequently prescribed for various infections, including those of the respiratory tract, skin, urinary tract, and central nervous system, such as meningitis.

The cephalosporin drug generations include the first, second, third, fourth, and fifth generations. First-generation cephalosporins are mainly effective against gram-positive bacteria like streptococcus and staphylococcus species, with limited efficacy against gram-negative organisms. They can be administered orally, via injection, or topically. Their clinical uses encompass the treatment of skin, respiratory, urinary tract, sexually transmitted, and ear infections, among others. These medications are available through hospital pharmacies, retail drugstores, and online platforms.

The cephalosporin drugs market research report is one of a series of new reports that provides cephalosporin drugs market statistics, including the cephalosporin drugs industry's global market size, regional shares, competitors with the cephalosporin drugs market share, detailed cephalosporin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cephalosporin drugs market. This cephalosporin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cephalosporin drugs market consists of sales of keflex, rocephin, and maxipime. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.